Alexion Pharmaceuticals (ALXN) : Jw Asset Management reduced its stake in Alexion Pharmaceuticals by 23.93% during the most recent quarter end. The investment management company now holds a total of 25,424 shares of Alexion Pharmaceuticals which is valued at $3.6 Million after selling 8,000 shares in Alexion Pharmaceuticals , the firm said in a disclosure report filed with the SEC on May 12, 2016.Alexion Pharmaceuticals makes up approximately 2.29% of Jw Asset Management’s portfolio.
Other Hedge Funds, Including , Mirae Asset Global Investments Ltd. reduced its stake in ALXN by selling 8,381 shares or 32.79% in the most recent quarter. The Hedge Fund company now holds 17,176 shares of ALXN which is valued at $2.4 Million. Alexion Pharmaceuticals makes up approx 0.07% of Mirae Asset Global Investments Ltd.’s portfolio. Pax World Management sold out all of its stake in ALXN during the most recent quarter. The investment firm sold 1,049 shares of ALXN which is valued $146,587. Stanley-laman Group Ltd. sold out all of its stake in ALXN during the most recent quarter. The investment firm sold 4,562 shares of ALXN which is valued $637,494.
Alexion Pharmaceuticals opened for trading at $139.29 and hit $143 on the upside on Friday, eventually ending the session at $142.52, with a gain of 2.51% or 3.49 points. The heightened volatility saw the trading volume jump to 9,75,544 shares. Company has a market cap of $31,927,330 M.
On the company’s financial health, Alexion Pharmaceuticals reported $1.11 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $1.13. The company had revenue of $701.00 million for the quarter, compared to analysts expectations of $711.95 million. The company’s revenue was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Company shares were Reiterated by Barclays on May 9, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 180 from a previous price target of $175 .Shares were Downgraded by Robert W. Baird on Mar 8, 2016 to ” Neutral” and Lowered the Price Target to $ 170 from a previous price target of $221 .Citigroup Initiated Alexion Pharmaceuticals on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $165.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.